COVAXIN™ (BBV152)
Coming Soon
The Company is actively engaged in discussions with the U.S. Food and Drug Administration to address its questions and resume the Company’s Phase 2/3 immuno-bridging and broadening clinical trial for COVAXIN™, OCU-002. We’ll provide more details as soon as possible.